Beau Bosko Toskich, M.D., is an interventional radiologist with specialty interest in interventional oncology. His clinical focus includes management of primary and metastatic liver cancer. His research interests include ablative applications of locoregional therapy and immunotherapy. Dr. Toskich has published and presented extensively on liver directed therapy, is the global lead investigator for an international study on combining radioembolizaiton with immunotherapy, has several funded investigator initiated clinical trials, serves on multiple societal and editorial boards, and is regarded as a key opinion leader by the pharmaceutical and medical device industry. He has a joint appointment with both the division of medical oncology and department of radiation oncology.

Prof. Beau Toskich has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Boston Scientific, Delcath, Eisai, Galvanize, Genentech, HistoSonics, Johnson & Johnson, Replimune, Sirtex Medical, Terumo, Turnstone Biologics, VIVOS.